Mercaptopurina (Mercaptopurine)

Mercaptopurine blocks the enzyme hypoxanthine‑guanine phosphoribosyltransferase, preventing the formation of active purine nucleotides. The drug is then incorporated into DNA and RNA, disrupting de novo purine synthesis and halting the replication of rapidly dividing cells, which underlies its antineoplastic and immunosuppressive effects.

The dosage of Mercaptopurina is individualized. A qualified prescriber determines the appropriate amount based on the specific indication, patient weight, renal and hepatic function, and concurrent therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

Mercaptopurina is classified as pregnancy category D, indicating evidence of fetal risk. It should be avoided unless the potential benefit justifies the risk. Breastfeeding is also discouraged because the drug can be excreted in milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their physician.

To order Mercaptopurina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Mercaptopurina is azathioprine, another thiopurine immunosuppressant. Both share a similar mechanism, but Mercaptopurina is often preferred in oncology because it provides more predictable pharmacokinetics and can be used at higher potency for leukemia treatment. Azathioprine is frequently chosen for long‑term maintenance in inflammatory bowel disease due to its oral convenience.

Mercaptopurina tablets should be stored at room temperature, below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms. No special refrigeration is required.

Mercaptopurina is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, with or without food, unless otherwise directed by their prescriber. The exact timing and frequency are determined by the treating physician based on the therapeutic indication.

The most critical risks include severe bone‑marrow suppression leading to pancytopenia, significant liver injury (hepatotoxicity), pancreatitis, and the rare development of secondary malignancies such as therapy‑related leukemia. Patients should report signs of infection, unusual bruising, persistent nausea, jaundice or severe abdominal pain to their healthcare provider promptly.

Mercaptopurina is contraindicated in individuals with known hypersensitivity to the drug, pregnant women (unless benefits outweigh risks), patients with severe hepatic impairment, uncontrolled infections, or those receiving concurrent high‑dose myelosuppressive therapy without appropriate monitoring. A thorough medical assessment is required before initiating treatment.